(Q37224257)

19 August 2017

1 reference

reason for preferred rank

title

Management of Thalassemia Major (Cooley’s Anemia) (English)

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

13 December 2022

Management of thalassemia major (Cooley's anemia) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1864823

13 December 2022

1 reference

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

13 December 2022

author name string

S. Piomelli

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1864823

13 December 2022

T. Loew

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1864823

13 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1864823

13 December 2022

publication date

1 June 1991

1 reference

full work available at URL

19 August 2017

https://api.elsevier.com/content/article/PII:S0889858818304313?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

https://api.elsevier.com/content/article/PII:S0889858818304313?httpAccept=text/plain

13 December 2022

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Hematology / Oncology Clinics of North America

13 December 2022

published in

1 reference

19 August 2017

volume

5

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

557-569

1 reference

Oral iron chelation with L1

19 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations

13 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Pyridoxal isonicotinoyl hydrazone: an effective iron-chelator after oral administration

13 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major

13 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Treatment of transfusional iron overload

13 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Current status of iron chelation therapy with deferoxamine

13 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Prospects for correction of thalassemia by genetic engineering

13 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

An evaluation of the potential of HBED as an orally effective iron-chelating drug

13 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Principles of iron chelating therapy

13 December 2022

11

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

13 December 2022

13

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

THE BIOCHEMISTRY OF DESFERRIOXAMINE AND ITS RELATION TO IRON METABOLISM

13 December 2022

14

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

13 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Chelation therapy and cardiac status in older patients with thalassemia major

13 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Bone marrow transplantation in patients with thalassemia

13 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Marrow transplantation in patients with advanced thalassemia

13 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Update on the hydroxypyridinone oral iron-chelating agents

13 December 2022

23

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen

13 December 2022

25

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Current strategies in the management of Cooley's anemia

13 December 2022

26

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Bone marrow transplantation for thalassemia

13 December 2022

27

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Animal toxicology of iron chelator L1

13 December 2022

29

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Continuous subcutaenous administration of deferoxamine in patients with iron overload

13 December 2022

31

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Reassessment of the Use of Desferrioxamine B in Iron Overload

13 December 2022

32

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Marrow transplantation for thalassaemia

13 December 2022

34

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

13 December 2022

37

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

TRANSFUSION THERAPY IN COOLEY'S ANEMIA: GROWTH AND HEALTH AS RELATED TO LONG-RANGE HEMOGLOBIN LEVELS. A PROGRESS REPORT.

13 December 2022

38

1 reference

https://api.crossref.org/works/10.1016/S0889-8588(18)30431-3

13 December 2022

Identifiers

1 reference